Cardiovascular outcomes by time-varying New York Heart Association class among patients with obstructive hypertrophic cardiomyopathy: a retrospective cohort study

References

• New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. Boston: Little, Brown and Co; 1994.
   Google Scholar
• Bennett JA, Riegel B, Bittner V, et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung. 2002;31(4):262–270. doi: 10.1067/mhl.2002.124554.
   PubMed Web of Science ®Google Scholar
• Ahmed A, Aronow WS, Fleg JL. Higher New York Heart Association classes and increased mortality and hospitalization in heart failure patients with preserved left ventricular function. Am Heart J. 2006;151(2):444–450. doi: 10.1016/j.ahj.2005.03.066.
   PubMed Web of Science ®Google Scholar
• Ahmed A. A propensity matched study of New York Heart Association class and natural history end points in heart failure. Am J Cardiol. 2007;99(4):549–553. doi: 10.1016/j.amjcard.2006.08.065.
   PubMed Web of Science ®Google Scholar
• Muntwyler J, Abetel G, Gruner C, et al. One-year mortality among unselected outpatients with heart failure. Eur Heart J. 2002;23(23):1861–1866. doi: 10.1053/euhj.2002.3282.
   PubMed Web of Science ®Google Scholar
• Lombardi C, Peveri G, Cani D, et al. In‐hospital and long‐term mortality for acute heart failure: analysis at the time of admission to the emergency department. ESC Heart Fail. 2020;7(5):2650–2661. doi: 10.1002/ehf2.12847.
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J. 2006;27(1):65–75. doi: 10.1093/eurheartj/ehi555.
   PubMed Web of Science ®Google Scholar
• Bouvy ML, Heerdink E, Leufkens H, et al. Predicting mortality in patients with heart failure: a pragmatic approach. Heart. 2003;89(6):605–609. doi: 10.1136/heart.89.6.605.
   PubMed Web of Science ®Google Scholar
• De Blois J, Simard S, Atar D, et al. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail. 2010;16(3):225–229. doi: 10.1016/j.cardfail.2009.12.002.
   PubMed Web of Science ®Google Scholar
• Störk S, Handrock R, Jacob J, et al. Epidemiology of heart failure in Germany: a retrospective database study. Clin Res Cardiol. 2017;106(11):913–922. doi: 10.1007/s00392-017-1137-7.
   PubMed Web of Science ®Google Scholar
• Citu IM, Citu C, Gorun F, et al. Using the NYHA classification as forecasting tool for hospital readmission and mortality in heart failure patients with COVID-19. J Clin Med. 2022;11(5):1382. doi: 10.3390/jcm11051382.
   PubMed Web of Science ®Google Scholar
• Ntusi NA, Shaboodien G, Badri M, et al. Clinical features, spectrum of causal genetic mutations and outcome of hypertrophic cardiomyopathy in South Africans. Cardiovasc J Afr. 2016;27(3):152–158. doi: 10.5830/CVJA-2015-075.
   PubMed Web of Science ®Google Scholar
• Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295–303. doi: 10.1056/NEJMoa021332.
   PubMed Web of Science ®Google Scholar
• Spirito P, Autore C, Rapezzi C, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119(13):1703–1710. doi: 10.1161/CIRCULATIONAHA.108.798314.
   PubMed Web of Science ®Google Scholar
• Wang X-H, Qiu J-B, Ju Y, et al. Reduction of heart failure rehospitalization using a weight management education intervention. J Cardiovasc Nurs. 2014;29(6):528–534. doi: 10.1097/JCN.0000000000000092.
   PubMed Web of Science ®Google Scholar
• Nasermoaddeli A, Miura K, Matsumori A, et al. Prognosis and prognostic factors in patients with hypertrophic cardiomyopathy in Japan: results from a nationwide study. Heart. 2007;93(6):711–715. doi: 10.1136/hrt.2006.095232.
   PubMed Web of Science ®Google Scholar
• Cui H, Schaff HV, Nishimura RA, et al. Latent outflow tract obstruction in hypertrophic cardiomyopathy: clinical characteristics and outcomes of septal myectomy. J Thorac Cardiovasc Surg. 2020;164(6):1863.e1–1869.e1. doi: 10.1016/j.jtcvs.2020.12.016.
   Web of Science ®Google Scholar
• Liu Q, Li D, Berger AE, et al. Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis. Sci Rep. 2017;7(1):11957. doi: 10.1038/s41598-017-12289-4.
   PubMedGoogle Scholar
• Geske JB, Ong KC, Siontis KC, et al. Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J. 2017;38(46):3434–3440. doi: 10.1093/eurheartj/ehx527.
   PubMed Web of Science ®Google Scholar
• Lakdawala N, Saberi S, Day S. New York Heart Association functional class and mortality in obstructive hypertrophic cardiomyopathy. Poster presented at: Heart Failure Society of America (HFSA). September 10–13, 2021, Denver, CO. 2021.
   Google Scholar
• Elliott PM, Gimeno JR, Tomé MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27(16):1933–1941. doi: 10.1093/eurheartj/ehl041.
   PubMed Web of Science ®Google Scholar
• Desai MY, Smedira NG, Bhonsale A, et al. Symptom assessment and exercise impairment in surgical decision making in hypertrophic obstructive cardiomyopathy: relationship to outcomes. J Thorac Cardiovasc Surg. 2015;150(4):928–935.e1. doi: 10.1016/j.jtcvs.2015.07.063.
   PubMed Web of Science ®Google Scholar
• Optum.com. Market clarity: linked EHR and claims data. 2022 [cited 2022 Dec]. https://www.optum.com/business/life-sciences/real-world-data/market-clarity-data.html.
   Google Scholar
• Burghardt A, van Buuren F, Dimitriadis Z, et al. Risk marker profiles in patients treated with percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy. Clin Res Cardiol. 2018;107(6):479–486. doi: 10.1007/s00392-018-1209-3.
   PubMed Web of Science ®Google Scholar
• Olivotto I, Cecchi F, Casey SA, et al. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001;104(21):2517–2524. doi: 10.1161/hc4601.097997.
   PubMed Web of Science ®Google Scholar
• Guttmann OP, Pavlou M, O'Mahony C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart. 2017;103(9):672–678. doi: 10.1136/heartjnl-2016-309672.
   PubMed Web of Science ®Google Scholar
• Fauchier L, Bisson A, Bodin A, et al. Ischemic stroke in patients with hypertrophic cardiomyopathy according to presence or absence of atrial fibrillation. Stroke. 2022;53(2):497–504. doi: 10.1161/STROKEAHA.121.034213.
   PubMed Web of Science ®Google Scholar
• Siontis KC, Geske JB, Ong K, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high‐risk population. J Am Heart Assoc. 2014;3(3):e001002.
   PubMed Web of Science ®Google Scholar
• Masri A, Kanj M, Thamilarasan M, et al. Outcomes in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a survival meta-analysis. Cardiovasc Diagn Ther. 2017;7(1):36–44. doi: 10.21037/cdt.2016.11.23.
   PubMed Web of Science ®Google Scholar
• Ye TTST, Siah QZ, Tan BY, et al. Prevalence of adverse cerebrovascular events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis. Stroke. 2022;53(Suppl_1):ATP208. doi: 10.1161/str.53.suppl_1.TP208.
   Google Scholar
• Guttmann OP, Pavlou M, O'Mahony C, et al. Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM risk‐CVA). Eur J Heart Fail. 2015;17(8):837–845. doi: 10.1002/ejhf.316.
   PubMed Web of Science ®Google Scholar